Press Releases

Date Title and Summary Additional Formats
Toggle Summary Dynavax Announces Fourth Quarter and Full Year 2018 Financial Results
Fourth quarter 2018 HEPLISAV-B ® net product revenue of $3.9 million Phase Ib/2 safety data for inhaled DV281 will be presented at the AACR Annual Meeting SD-101 demonstrates consistent and meaningful clinical benefit to anti-PD-1 therapy Conference call to be held today at 4:30 p.m. ET / 1:30 p.m.
View HTML
Toggle Summary Dynavax Technologies to Report Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on February 26
BERKELEY, Calif. , Feb. 12, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX), a fully-integrated biopharmaceutical company focused on discovering and developing novel vaccines and immuno-oncology therapeutics, will report its fourth quarter and full year 2018 financial
View HTML
Toggle Summary Heather Rowe Named Dynavax’s Vice President of Investor Relations and Corporate Communications
BERKELEY, Calif. , Jan. 29, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX), a fully-integrated biopharmaceutical company focused on discovering and developing novel vaccines and immuno-oncology therapeutics, today announced that Heather Rowe has been appointed vice
View HTML
Toggle Summary Sam’s Club and Dynavax Technologies Corporation Announce Collaboration to Make HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted] Available to Sam’s Club Patients
BERKELEY, Calif. , Jan. 08, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX), a leader in developing immunotherapies based on toll-like receptor (TLR) biology, and Sam’s Club, a leading membership warehouse club offering superior products, savings and services to millions of
View HTML
Toggle Summary Dynavax to Present at 37th Annual J.P. Morgan Healthcare Conference
BERKELEY, Calif. , Jan. 03, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX), a fully-integrated biopharmaceutical company focused on discovering and developing novel vaccines and immuno-oncology therapeutics, today announced that Eddie Gray , Chief Executive Officer, will
View HTML
Toggle Summary Dynavax Reports Third Quarter 2018 Financial Results, Progress on HEPLISAV-B Launch, and Updated SD-101 Data in Three Patient Populations
Conference Call to be held Today at 4:30pm ET / 1:30pm PT BERKELEY, Calif. , Nov. 05, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the third quarter ended September 30, 2018 along with an update on the launch progress of HEPLISAV-B
View HTML
Toggle Summary Dynavax to Host Third Quarter 2018 Financial Results Conference Call
BERKELEY, Calif. , Oct. 29, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it will report financial results for the third quarter ended September 30, 2018 after market close on Monday, November 5, 2018 , and host a conference call that day to review
View HTML
Toggle Summary Dynavax’s SD-101 in Combination with KEYTRUDA® (pembrolizumab) Continues to Show a 70% Overall Response Rate in Advanced Melanoma Patients According to Data Presented Today at the ESMO 2018 Congress
- 70% overall response rate (33/47 patients) at 2 mg dose of SD-101 includes 17 additional patients - -Progression free survival, response rate in patients with PDL-1 negative tumors and biomarker activity supports clinical impact of SD-101’s activity- - Conference call and webcast to review all
View HTML
Toggle Summary Dynavax Technologies and Quantum Leap Healthcare Collaborative Announce Selection of SD-101 Combined with KEYTRUDA® (pembrolizumab) in the I-SPY 2 TRIAL For Breast Cancer
BERKELEY, Calif. and SAN FRANCISCO , Oct. 15, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) and Quantum Leap Healthcare Collaborative™ (QLHC) announced today that the immunotherapy combination of Dynavax’s proprietary investigational compound SD-101 and KEYTRUDA®
View HTML
Toggle Summary Dynavax to Present New Data for SD-101 in Combination with KEYTRUDA® (pembrolizumab) at the European Society for Medical Oncology 2018 Congress
BERKELEY, Calif. , Oct. 09, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) announced today that data will be presented from its ongoing Phase 1b/2 study investigating SD-101, Dynavax's intratumoral TLR9 agonist, in combination with KEYTRUDA ® (pembrolizumab), an anti-PD-1
View HTML